Predictive factors for recurrence after complete metastasectomy in metastatic kidney cancer patients

In this retrospective study, published in Science Direct this month, researchers were looking to identify the factors that would help to predict whether the cancer would come back after surgical removal of renal cell carcinoma (RCC) metastases (metastasectomy). Complete metastasectomy is expected to improve the survival of patients with metastatic RCC. However, for many patients […]

read more

Long-term risk of recurrence after surgery for kidney cancer

A recent study published in the journal European Urology investigated the long-term risk of recurrence in people who had had a nephrectomy for the treatment of localised renal cell carcinoma (RCC) in order to determine the usefulness of long-term follow-up (surveillance). A retrospective analysis of 1943 patients who took part in the ECOG E2805 clinical […]

read more

Incidence and pattern of recurrence of kidney cancer after robotic partial nephrectomy

A recent study has shown the incidence and pattern of recurrence of renal cell carcinoma (RCC) in patients who underwent robotic partial nephrectomy for a small renal mass between September 2009 and March 2018. A total of 335 patients with a small renal mass underwent robotic partial nephrectomy, 269 patients of which were found to […]

read more

Sorafenib versus observation following surgery for metastatic kidney cancer

A potential treatment for a selected group of patients with metastatic renal cell carcinoma (RCC) is nephrectomy followed by surgery to remove metastases (radical metastasectomy). After surgery, patients are usually followed by observation or treated with anti-cancer drugs. The RESORT clinical trial assessed the potential benefit of treatment with sorafenib after radical metastasectomy compared with […]

read more

Potential kidney cancer test in development

A Swedish biotechnology company, Elypta, has recently been awarded an EU grant for the development of a new test for the diagnosis of renal cell carcinoma (RCC). The grant of £2.4m will be used to run a clinical trial to validate Elypta’s technology as a tool for monitoring patients who have been treated for RCC […]

read more

High levels of distress among people with kidney cancer

A recent study published in BJU International reports high levels of distress among people with the most common form of kidney cancer, renal cell carcinoma (RCC). Four hundred and fifty (450) people were surveyed online from April to June 2017. Most patients where white (93 %) and more than half were women (56 %). The mean […]

read more

ESMO 2018: Adjuvant axitinib versus placebo in patients at high risk of RCC recurrance

Results from the latest adjuvant study with a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), axitinib (Inlyta), were presented at the European Society of Medical Oncology (ESMO) 2018 conference in Munich over the weekend. Results of clinical trials assessing adjuvant therapy for intermediate- and high-risk renal cell carcinoma (RCC) with VEGF TKIs have […]

read more

Adjuvant sunitinib declined by European Medicines Agency committee

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended against the use of sunitinib (Sutent) as an adjuvant treatment of adult patients at a high risk of recurrent renal cell carcinoma (RCC) following nephrectomy (surgical removal of the cancerous kidney). However, the CHMP’s recommendation is not binding […]

read more

Status of adjuvant therapy for the treatment of kidney cancer

Dr Naomi Haas from Abramson Cancer Centre, Philadelphia, presented an overview of adjuvant therapy with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) in patients with high-risk renal cell carcinoma (RCC) at the American Society for Clinical Oncology Genitourinary (ASCO GU) 2018 meeting in San Francisco this month. Over the past few years, three […]

read more

Sunitinib approved by the FDA for adjuvant treatment of advanced kidney cancer

The US Food and Drug Administration (FDA) has approved sunitinib (Sutent) for adjuvant treatment of adults who have had their kidney cancer removed, but who are at high risk of the cancer returning. Sunitinib is a tyrosine kinase inhibitor (TKI) that works by blocking several enzymes that promote cell growth and the formation of new […]

read more
Showing 1 to 10 of 12 results
  TOP